Adverse Event Reporting in Clinical Trials Frontiers Post marketing safety of anakinra and canakinumab: a real world pharmacovigilance study based on FDA adverse event reporting system In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Documenting Adverse Events Applied Clinical Trials Online